TY - JOUR
KW - Adult
KW - Age Factors
KW - Americas
KW - Bupropion/economics/therapeutic use
KW - Cost-Benefit Analysis
KW - Drug Costs/statistics & numerical data
KW - Europe
KW - Female
KW - Health Care Costs/statistics & numerical data
KW - Humans
KW - Male
KW - Markov Chains
KW - Middle Aged
KW - Nicotine/administration & dosage/economics/therapeutic use
KW - Primary Health Care/economics/methods
KW - Recurrence
KW - Sex Factors
KW - Smoking Cessation/economics/methods
KW - Tobacco Use Disorder/drug therapy/economics
KW - Treatment Outcome
AU - J. Cornuz
AU - A. Gilbert
AU - C. Pinget
AU - P. McDonald
AU - K. Slama
AU - E. Salto
AU - F. Paccaud
A1 - 
AB - OBJECTIVE: To estimate the incremental cost-effectiveness of the first-line pharmacotherapies (nicotine gum, patch, spray, inhaler, and bupropion) for smoking cessation across six Western countries-Canada, France, Spain, Switzerland, the United States, and the United Kingdom. DESIGN AND STUDY POPULATION: A Markov-chain cohort model to simulate two cohorts of smokers: (1) a reference cohort given brief cessation counselling by a general practitioner (GP); (2) a treatment cohort given counselling plus pharmacotherapy. Effectiveness expressed as odds ratios for quitting associated with pharmacotherapies. Costs based on the additional physician time required and retail prices of the medications. INTERVENTIONS: Addition of each first-line pharmacotherapy to GP cessation counselling. MAIN OUTCOME MEASURES: Cost per life-year saved associated with pharmacotherapies. RESULTS: The cost per life-year saved for counselling only ranged from US190 dollars in Spain to 773 dollars in the UK for men, and from 288 dollars in Spain to 1168 dollars in the UK for women. The incremental cost per life-year saved for gum ranged from 2230 dollars for men in Spain to 7643 dollars for women in the US; for patch from 1758 dollars for men in Spain to 5131 dollars for women in the UK; for spray from 1935 dollars for men in Spain to 7969 dollars for women in the US; for inhaler from 3480 dollars for men in Switzerland to 8700 dollars for women in France; and for bupropion from 792 dollars for men in Canada to 2922 dollars for women in the US. In sensitivity analysis, changes in discount rate, treatment effectiveness, and natural quit rate had the strongest influences on cost-effectiveness. CONCLUSIONS: The cost-effectiveness of the pharmacotherapies varied significantly across the six study countries, however, in each case, the results would be considered favourable as compared to other common preventive pharmacotherapies.
BT - Tobacco control
C5 - Financing & Sustainability
CP - 3
CY - England
DO - 10.1136/tc.2005.011551
IS - 3
JF - Tobacco control
N2 - OBJECTIVE: To estimate the incremental cost-effectiveness of the first-line pharmacotherapies (nicotine gum, patch, spray, inhaler, and bupropion) for smoking cessation across six Western countries-Canada, France, Spain, Switzerland, the United States, and the United Kingdom. DESIGN AND STUDY POPULATION: A Markov-chain cohort model to simulate two cohorts of smokers: (1) a reference cohort given brief cessation counselling by a general practitioner (GP); (2) a treatment cohort given counselling plus pharmacotherapy. Effectiveness expressed as odds ratios for quitting associated with pharmacotherapies. Costs based on the additional physician time required and retail prices of the medications. INTERVENTIONS: Addition of each first-line pharmacotherapy to GP cessation counselling. MAIN OUTCOME MEASURES: Cost per life-year saved associated with pharmacotherapies. RESULTS: The cost per life-year saved for counselling only ranged from US190 dollars in Spain to 773 dollars in the UK for men, and from 288 dollars in Spain to 1168 dollars in the UK for women. The incremental cost per life-year saved for gum ranged from 2230 dollars for men in Spain to 7643 dollars for women in the US; for patch from 1758 dollars for men in Spain to 5131 dollars for women in the UK; for spray from 1935 dollars for men in Spain to 7969 dollars for women in the US; for inhaler from 3480 dollars for men in Switzerland to 8700 dollars for women in France; and for bupropion from 792 dollars for men in Canada to 2922 dollars for women in the US. In sensitivity analysis, changes in discount rate, treatment effectiveness, and natural quit rate had the strongest influences on cost-effectiveness. CONCLUSIONS: The cost-effectiveness of the pharmacotherapies varied significantly across the six study countries, however, in each case, the results would be considered favourable as compared to other common preventive pharmacotherapies.
PP - England
PY - 2006
SN - 1468-3318; 0964-4563
SP - 152
EP - 159
EP - 
T1 - Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: A multinational comparison
T2 - Tobacco control
TI - Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: A multinational comparison
U1 - Financing & Sustainability
U2 - 16728744
U3 - 10.1136/tc.2005.011551
VL - 15
VO - 1468-3318; 0964-4563
Y1 - 2006
ER -